GMDA News and Press, Gamida Cell Ltd. From 04/27/22

Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Update...

Gainers: Avadel Pharmaceuticals (AVDL) +30%. AgeX Therapeutics (AGE) +9%. Helius Medical Technologies (HSDT) +7%. Quipt Home Medical (QIPT) +7%. Gamida Cell (GMDA) +5%. Losers: Protagonist Therapeutics (PTGX) -47%. Nkarta (NKTX) -14%. ...

Penny stocks have earned their place in the stock market today for their high-risk & high-reward reputation. But something that most new traders fail to realize is that these cheap stocks aren’t just “lottery tickets” to buy blindly. There are plenty of ways to make...

Jiuzi Holdings (JZXN) +88% enters into an equity acquisition agreement to acquire automobile sales serviceshop operator under top China automaker Geely Auto's premium electronic vehicle brand geometry. Avadel Pharmaceuticals (AVDL) +35% provides comment on Recent trading activity. Gamida...

Gamida Cell (NASDAQ:GMDA) said the U.S. Food and Drug Administration (FDA) lifted a clinical hold for a cryopreserved formulation of GDA-201. The company added that the FDA cleared its investigational new drug (IND) application to start a trial of its NK cell therapy candidate GDA-2...

Company advancing plans to begin Phase 1/2 study in patients with follicular and diffuse large B-cell lymphomas Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious dise...

Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Oral p...

Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant Study ...

Shares of Gamida Cell Ltd. (NASDAQ:GMDA) traded today at $17.89, eclipsing its 52-week high. This new high was reached on above average trading volume as 24 million shares traded hands, while the average 30-day volume is approximately 310,000 shares. Gamida Cell Ltd. has overhead space w...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, announced that company management will present at the upcoming 21 st Annual Needham Virtual Healthcare Conferenc...